Bingham Osborn & Scarborough LLC continued to hold its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,412 shares of the specialty pharmaceutical company’s stock at the end of the second quarter. Jazz Pharmaceuticals PLC accounts for about 0.2% of Bingham Osborn & Scarborough LLC’s portfolio, making the stock its 28th largest position. Bingham Osborn & Scarborough LLC’s holdings in Jazz Pharmaceuticals PLC were worth $2,397,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Rice Hall James & Associates LLC bought a new stake in Jazz Pharmaceuticals PLC during the second quarter valued at about $2,316,000. C WorldWide Group Holding A S boosted its stake in Jazz Pharmaceuticals PLC by 6.7% in the second quarter. C WorldWide Group Holding A S now owns 105,048 shares of the specialty pharmaceutical company’s stock valued at $16,335,000 after buying an additional 6,583 shares in the last quarter. First Trust Advisors LP bought a new stake in Jazz Pharmaceuticals PLC during the second quarter valued at about $2,280,000. Monarch Partners Asset Management LLC boosted its stake in Jazz Pharmaceuticals PLC by 20.0% in the second quarter. Monarch Partners Asset Management LLC now owns 72,197 shares of the specialty pharmaceutical company’s stock valued at $11,227,000 after buying an additional 12,022 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its stake in Jazz Pharmaceuticals PLC by 6.0% in the second quarter. Schwab Charles Investment Management Inc. now owns 185,666 shares of the specialty pharmaceutical company’s stock valued at $28,872,000 after buying an additional 10,446 shares in the last quarter. 86.43% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals PLC (JAZZ) opened at 142.71 on Friday. The company has a market cap of $8.57 billion, a price-to-earnings ratio of 21.98 and a beta of 1.10. The stock’s 50 day moving average is $154.90 and its 200 day moving average is $146.69. Jazz Pharmaceuticals PLC has a 52-week low of $95.80 and a 52-week high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.85 by $0.13. The company had revenue of $394.39 million for the quarter, compared to the consensus estimate of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The firm’s revenue was up 3.5% compared to the same quarter last year. During the same period in the previous year, the business posted $2.67 earnings per share. On average, analysts predict that Jazz Pharmaceuticals PLC will post $10.87 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Bingham Osborn & Scarborough LLC Has $2,397,000 Position in Jazz Pharmaceuticals PLC (JAZZ)” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.dailypolitical.com/2017/08/13/bingham-osborn-scarborough-llc-has-2397000-position-in-jazz-pharmaceuticals-plc-jazz.html.

Several analysts recently issued reports on the stock. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $177.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Thursday. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $177.00 price target (down from $178.00) on shares of Jazz Pharmaceuticals PLC in a report on Thursday. Cowen and Company reaffirmed an “outperform” rating and issued a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a report on Wednesday. Deutsche Bank AG set a $175.00 price target on shares of Jazz Pharmaceuticals PLC and gave the company a “buy” rating in a report on Wednesday. Finally, Royal Bank Of Canada reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals PLC in a report on Wednesday. One research analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $182.72.

In other news, EVP Suzanne Sawochka Hooper sold 420 shares of the firm’s stock in a transaction on Friday, June 23rd. The stock was sold at an average price of $160.00, for a total value of $67,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Rick E. Winningham sold 5,000 shares of the firm’s stock in a transaction on Thursday, June 1st. The shares were sold at an average price of $150.00, for a total value of $750,000.00. Following the completion of the sale, the director now owns 10,391 shares of the company’s stock, valued at $1,558,650. The disclosure for this sale can be found here. Over the last three months, insiders have sold 10,600 shares of company stock valued at $1,641,720. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.